MDS Analytical Technologies Acquires Blueshift Biotechnologies
News Oct 21, 2008
The acquisition of Blueshift Biotechnologies, a developer of screening platforms for life sciences research and maker of the IsoCyte™ benchtop laser scanning cytometer, expands MDS Analytical Technologies' capabilities in cellular analysis, and further strengthens the company's global sales and service offering.
High Content Screening (HCS) and High Content Analysis (HCA) are growing trends in both pharmaceutical drug screening and life sciences research. MDS Analytical Technologies' cellular imaging product line now includes imaging systems and software that provide life sciences and drug discovery researchers with a more complete solution to conduct HCS and HCA. Cellular imaging provides intracellular information on compound effects for a large variety of cellular processes. Blueshift Biotechnologies' IsoCyte™ instrument conducts rapid image analysis of large populations of cells in a microtiter plate whole-well format. Whole-well, rapid cellular analysis enables a cost-effective solution for the adoption of HCS and HCA into high throughput screening environments.
“This acquisition fills a gap in our current product portfolio, allowing us to offer our pharmaceutical research customers fast and simple cellular analysis with a line of instrumentation that images the whole well at true high throughput screening rates,” said Andy Boorn, president of MDS Analytical Technologies. “There are currently fourteen IsoCyte instruments installed at academic, biotech and pharmaceutical companies in North America. With our extensive global sales force, we have the ability to bring this novel product to a wider global market.”
“We are very excited about this opportunity for Blueshift Biotechnologies to merge into a world-class company like MDS Analytical Technologies,” stated Evan Cromwell, president of Blueshift Biotechnologies. “The breadth and strength of its sales and marketing efforts mean that we will be able to increase awareness of this unique high-throughput imaging tool in new markets.”
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018